重症创伤患者万古霉素给药:VANCTIC研究
本研究为回顾性研究,纳入39个月内入住一级创伤ICU、疑似严重感染并按「药房给药」方案接受经验性万古霉素、且稳态谷浓度采血合格的重症创伤患者70例。中位年龄47.5岁,中位损伤严重度评分28,中位肌酐清除率159.1 mL/min,中位ARCTIC评分7。中位负荷剂量24.6 mg/kg,初始维持剂量17.71 mg/kg,47.14%起始每8小时给药、45.71%起始每12小时给药。仅15.71%达到初始治疗谷浓度(14.5–20.5 mg/L),42.86%低于10 mg/L,8.57%高于20.5 mg/L;急性肾损伤发生率按IDSA/ASHP万古霉素指南为10%,按AKIN标准为11.4%。作者认为其指南依从的间歇性万古霉素方案不足以达到15–20 mg/L谷浓度。
要点
- 重症创伤患者中位肌酐清除率159.1 mL/min、中位ARCTIC评分7,提示存在 augmented renal clearance(ARC)。
- 按「药房给药」方案,中位万古霉素负荷剂量24.6 mg/kg、初始维持剂量17.71 mg/kg,47.14%每8小时、45.71%每12小时给药。
- 仅15.71%患者达到初始治疗谷浓度14.5–20.5 mg/L,42.86%低于10 mg/L,8.57%高于20.5 mg/L。
- 急性肾损伤发生率按IDSA/ASHP万古霉素指南为10%,按AKIN标准为11.4%。
- 作者结论:指南依从的间歇性万古霉素方案不足以在重症创伤患者中达到15–20 mg/L谷浓度。
适用人群与场景
- 39个月内入住一级创伤ICU、疑似严重感染、按「药房给药」方案接受经验性万古霉素、且稳态谷浓度采血合格的重症创伤患者。
诊断标准与关键阈值
- 初始治疗谷浓度定义为14.5 mg/L至20.5 mg/L。
- IDSA/ASHP指南推荐严重MRSA感染的万古霉素谷浓度为15 mg/L至20 mg/L。
处置流程与药物剂量
- 中位万古霉素负荷剂量24.6 mg/kg。
- 中位初始维持剂量17.71 mg/kg。
- 47.14%患者起始每8小时给药,45.71%患者起始每12小时给药。
研究设计与关键结果
- 回顾性研究,筛查197例,纳入70例符合标准的重症创伤患者;中位年龄47.5岁,中位损伤严重度评分28。
- 中位肌酐清除率159.1 mL/min,中位ARCTIC评分7。
- 仅15.71%达到初始治疗谷浓度(14.5–20.5 mg/L);42.86%低于10 mg/L,8.57%高于20.5 mg/L。
- 急性肾损伤发生率按IDSA/ASHP万古霉素指南为10%,按AKIN标准为11.4%。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:治疗性,level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,其指南依从的间歇性万古霉素方案不足以在重症创伤患者中达到15–20 mg/L的谷浓度。
指南或共识出处
- Infectious Diseases Society of America(IDSA)与American Society of Health-System Pharmacists(ASHP)万古霉素谷浓度指南(原文未注明年份)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guidelines from the Infectious Diseases Society of America and the American Society of Health-System Pharmacists recommend vancomycin troughs of 15 mg/L to 20 mg/L for serious methicillin-resistant Staphylococcus aureus infections. The pharmacokinetics of vancomycin are altered in critically ill patients, leading to inadequate serum levels. Rates of initial therapeutic vancomycin troughs have ranged from 17.6% to 33% using intermittent infusions (i.e., 15-20 mg/L) and approximately 60% using continuous infusions (i.e., 15-25 mg/L) in critically ill trauma patients (1-4). We hypothesized that our dosing protocol would achieve higher rates of initial therapeutic troughs compared with previously published reports due to more aggressive loading doses than those seen in previously published reports.
METHODS: This was a retrospective study of all critically ill trauma patients admitted to a Level I trauma intensive care unit over a 39-month period who had a suspected serious infection, who were treated with empiric vancomycin per the "pharmacy to dose" protocol, and who had an appropriately drawn steady state trough level. The primary outcome was the rate of initial therapeutic troughs, which was defined as 14.5 mg/L to 20.5 mg/L.
RESULTS: One hundred ninety-seven patients were screened. Seventy patients met inclusion criteria. The study cohort had a median age of 47.5 years and a median Injury Severity Score of 28. Augmented renal clearances were observed, with a median creatinine clearance of 159.1 mL/min and a median Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) score of 7. The median vancomycin loading dose was 24.6 mg/kg with an initial maintenance dose of 17.71 mg/kg. An every eight hour dosing interval was initiated on 47.14% of the patients, and 45.71% of the patients were initially started on an every 12 hour dosing interval. Only 15.71% of the study patients achieved an initial therapeutic trough; 42.86% were less than 10 mg/L, and 8.57% were greater than 20.5 mg/L. Acute kidney injury occurred in 10% based on the Infectious Diseases Society of America/American Society of Health-System Pharmacists vancomycin guidelines and in 11.4% based on the Acute Kidney Injury Network criteria.
CONCLUSION: Our incidence of initial therapeutic troughs was slightly below previously reported studies. Based on our results, which are consistent with previous literature, it would appear that our guideline-adherent protocol of intermittent vancomycin is insufficient to achieve troughs of 15 mg/L to 20 mg/L.
LEVEL OF EVIDENCE: Therapeutic, level III.
参考来源
- Villanueva RD, Talledo O, Neely S, et al. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study. J Trauma Acute Care Surg. 2019. PMID: 31464871. doi:10.1097/TA.0000000000002492
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。